VSTM vs Biotech Stocks
| Ticker | Price | Price Target | Up/downside |
| VSTM | $1.13 | $5.50 | +386.73% |
| GRCL | $3.05 | $19.00 | +522.95% |
| MIST | $7.06 | $10.00 | +41.64% |
| CRMD | $5.41 | $22.00 | +306.65% |
| High | $8.00 |
|---|---|
| Median | $5.00 |
| Low | $5.00 |
| Average | $5.80 |
| Current Price | $1.11 |
What does target price mean in stocks?
Target Price in Stocks
- Target Price Advantage. A target price is an estimate of where an analyst thinks a stock will go. ...
- Target Price Disadvantage. The analysts could be wrong. ...
- Advantage of Starting from the Actual Price. ...
- Disadvantage of Starting from the Actual Price. ...
Should I Buy Target stock?
Target Corp. said Thursday it is testing a store in California that was retrofitted to become the retailer's first net-zero energy store, generating more power than its needs annually. The Minneapolis-based company's location in Vista, California ...
What does target price mean?
Target price may mean: A stock valuation at which a trader is willing to buy or sell a stock. Target pricing – the price at which a seller projects that a buyer will buy a product. Topics referred to by the same term. This disambiguation page lists articles associated with the title Target price. If an internal link led you here, you may wish ...
What is target price in stock market?
If we look at the average trading volume of 3.73M shares, VLTA reached to a volume of 3252360 in the most recent trading day, which is why market watchdogs consider the stock to be active. Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for VLTA shares is $5.29 per share.
What is Verastem's consensus rating and price target?
According to the issued ratings of 5 analysts in the last year, the consensus rating for Verastem stock is Buy based on the current 5 buy ratings f...
Do Wall Street analysts like Verastem more than its competitors?
Analysts like Verastem stock more than the stock of other Medical companies. The consensus rating score for Verastem is 3.00 while the average cons...
Do MarketBeat users like Verastem more than its competitors?
MarketBeat users like Verastem stock more than the stock of other Medical companies. 67.99% of MarketBeat users gave Verastem an outperform vote wh...
Does Verastem's stock price have much upside?
According to analysts, Verastem's stock has a predicted upside of 165.88% based on their 12-month price targets.
What analysts cover Verastem?
Verastem has been rated by Cantor Fitzgerald , HC Wainwright , and Royal Bank of Canada in the past 90 days.
Component Grades
We have 9 different ratings for every stock to help you appreciate its future potential. You can unlock it all now.
The Trend in the Analyst Price Target
Over the past 18 months, VSTM's average price target has gone up $2.42.
The Trend in the Broker Recommendations
VSTM's average broker recommendation rating improved by 0.75 over the prior 31 days.
What is the VSTM symbol?
Verastem trades on the NASDAQ under the ticker symbol "VSTM."
What is the rating of Verastem?
Verastem has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.
What is MarketBeat community ratings?
MarketBeat's community ratings are surveys of what our community members think about Verastem and other stocks. Vote “Outperform” if you believe VSTM will outperform the S&P 500 over the long term. Vote “Underperform” if you believe VSTM will underperform the S&P 500 over the long term. You may vote once every thirty days.
How many research reports has Verastem been subject to?
Verastem has only been the subject of 1 research reports in the past 90 days.
Does Verastem pay dividends?
Verastem does not currently pay a dividend.
What is VSTM in medicine?
Verastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to advancing new medicines for patients battling cancer , today announced that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation for the combination of its investigational RAF/MEK inhibitor VS-6766, with defactinib, its FAK inhibitor, for the treatment of all patients with recurrent low-grade serous ovarian cancer (LGSOC) regardless of KRAS status after one or more prior lines of therapy, including platinum-based chemotherapy.
When is the Verastem conference?
(Nasdaq: VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today announced that the Company will present at the 2021 Jefferies Virtual Healthcare Conference on Tuesday, June 1, 2021 at 4:00 p.m. ET.
What is Verastem oncology?
BOSTON, July 06, 2021--Verastem Oncology (Nasdaq:VSTM), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today announced the grant of options to purchase 16,250 shares of its common stock and the grant of 8,125 restricted stock units (RSUs) to three new employees. The awards were granted as an inducement material to the employees' acceptance of employment with Verastem Oncology in accordance with Nasdaq Listing Rule 5635 (c) (4). The options have an ex
What is BTD in biotech?
The biotech's shares are perking up today in response to the decision by the Food and Drug Administration (FDA) to grant the coveted Breakthrough Therapy Designation (BTD) for the company's experimental cancer-combo therapy.
Is BTD a treatment for ovarian cancer?
The FDA granted the drug BTD as a potential treatment for patients with recurrent low-grade serous ovarian cancer, regardless of KRAS status after one or more prior lines of therapy, including platinum-based chemotherapy. Business Wire • last month.
Stock Price Forecast
The 3 analysts offering 12-month price forecasts for Verastem Inc have a median target of 6.00, with a high estimate of 8.00 and a low estimate of 5.00. The median estimate represents a +339.56% increase from the last price of 1.37.
Analyst Recommendations
The current consensus among 3 polled investment analysts is to Buy stock in Verastem Inc. This rating has held steady since December, when it was unchanged from a Buy rating. Move your mouse over past months for detail
How is Verastem target price determined?
Verastem target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Verastem target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
How does Verastem recommend stocks?
Verastem's analyst stock recommendations are determined by taking an average estimate of all analysts we track and classifying them as Strong Buy, Buy, Hold, Strong Sell, or Sell. Ratings generally communicate what analysts sense about Verastem stock, and they use a lot of effort and time to analyze it and arrive at a rating. That suggests that analyst recommendations are the outcome of an objective and thorough examination of Verastem's financials, market performance, and future outlook by experienced professionals. Verastem's historical ratings below, therefore, can serve as a valuable tool for investors.
How often does Verastem give ratings?
Most Verastem analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Verastem stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Verastem, talking to its executives and customers, or listening to those companies' conference calls.
What is mean reversion in Verastem?
This tendency of Verastem's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy. Please use the tools below to analyze the current value of Verastem in the context of predictive analytics.
Where do analysts publish their price targets?
Note that most analysts generally publish their price targets in research reports on specific companies , along with recommendations for the company's stock.Although price targets are often quoted in the financial news media, there could be a delay between the publication of the latest analyst outlook on Verastem and the information provided on this page.
What is the data in Verastem?
The data published in Verastem's official financial statements usually reflect Verastem's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Verastem. For example, before you start analyzing numbers published by Verastem accountants, it's critical to develop an understanding of what Verastem's liquidity, profitability, and earnings quality are in the context of the Healthcare space in which it operates.
What is an investment theme?
A typical investing theme is an unweighted collection of up to 20 funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of equities with common characteristics such as industry and growth potential, volatility, or market segment.
Does Verastem have a sell signal?
Also, there is a general sell signal from the relation between the two signals where the long-term average is above the short-term average.
Is Verastem a negative stock?
The Verastem stock holds several negative signals and despite the positive trend, we believe Verastem will perform weakly in the next couple of days or weeks. Therefore, we hold a negative evaluation of this stock. Due to some small weaknesses in the technical picture we have downgraded our analysis conclusion for this stock since the last evaluation from a Hold/Accumulate to a Sell candidate.
Is Verastem stock A Buy?
Verastem holds several negative signals and is within a very wide and falling trend, so we believe it will still perform weakly in the next couple of days or weeks. We therefore hold a negative evaluation of this stock. Due to some small weaknesses in the technical picture we have downgraded our analysis conclusion for this stock since the last evaluation from a Sell to a Strong Sell candidate.
Sales
- Verastem Inc (NASDAQ:VSTM) announced its quarterly earnings data on Thursday, May, 9th. The biopharmaceutical company reported ($0.51) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.46) by $0.05. The biopharmaceutical company had revenue of $1.67 million for the quarter, compared to analysts' expectations of $2.84 million. Verastem had …
Release
- Verastem is scheduled to release their next quarterly earnings announcement on Wednesday, August 14th 2019. View Earnings Estimates for Verastem.
Risks
- 7 Wall Street analysts have issued 12 month price objectives for Verastem's stock. Their forecasts range from $2.50 to $17.00. On average, they expect Verastem's stock price to reach $9.7857 in the next twelve months. This suggests a possible upside of 619.5% from the stock's current price. View Analyst Price Targets for Verastem.
Ratings
- 7 Wall Street analysts have issued \"buy,\" \"hold,\" and \"sell\" ratings for Verastem in the last year. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus recommendation of \"Buy.\" View Analyst Ratings for Verastem. News headlines about VSTM stock have trended neutral on Monday, InfoTrie reports. The research firm scores the sentiment …
Ownership
- Verastem's stock is owned by many different of institutional and retail investors. Top institutional investors include BlackRock Inc. (7.80%), Howland Capital Management LLC (0.31%), Rhumbline Advisers (0.15%), California Public Employees Retirement System (0.13%), B. Riley Financial Inc. (0.08%) and Raymond James & Associates (0.07%). Company insiders that own Verastem stoc…
Business
- Verastem has a market capitalization of $100.48 million and generates $26.72 million in revenue each year. The biopharmaceutical company earns $-72,430,000.00 in net income (profit) each year or ($1.37) on an earnings per share basis. Verastem employs 169 workers across the globe.
Location
- Verastem's mailing address is 117 KENDRICK STREET SUITE 500, NEEDHAM MA, 02494. The biopharmaceutical company can be reached via phone at 781-292-4200 or via email at [email protected].